Flagship Pioneering unveiled Etcelera, a new startup formed by combining three of the firm’s portfolio companies. Etcelera’s approach to drug R&D focuses on “causal intelligence,” which Flagship defines as predicting and understanding cause and effect in biology.
The post Flagship Merges 3 Startups to Turn Cause and Effect Insights Into Novel Medicines appeared first on MedCity News.
